美国食品和药物管理局批准了Telix的TLX101-Px脑瘤成像剂. FDA accepts Telix's resubmission for TLX101-Px brain tumor imaging agent.

美国FDA已接受Telix制药公司重新提交的TLX101-Px (Pixclara) 新药申请,该新药是用于脑瘤的PET成像剂. The U.S. FDA has accepted Telix Pharmaceuticals' resubmitted New Drug Application for TLX101-Px (Pixclara), a PET imaging agent for brain tumors. 该药物已获得孤儿药和快速通道指定,目标决定日期为2026年9月. The drug has received Orphan Drug and Fast Track designations, with a target decision date of September 2026. 目的是帮助医生区分复发性结质瘤与治疗相关的变化,解决重大医学需求. It aims to help doctors distinguish recurrent glioma from treatment-related changes, addressing a significant medical need.